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Abstract  
BACKGROUND: The role of glucagon like peptide-1 (GLP-1) has become a new scientific interest 
in the field of pathophysiology of type 1 diabetes mellitus (T1DM), but the results of the published 
studies were not uniform. Following that observation, the aim of our study was to measure fasting and 
postprandial GLP-1 concentrations in T1DM patients and in healthy controls and to examine the 
difference in those concentrations between the two groups of subjects.  
METHODS: The cross-sectional study included 30 C-peptide negative T1DM patients, median age 
37 years (20-59), the disease duration 22 years (3-45), and 10 healthy controls, median age 30 years 
(27-47). Fasting and postprandial total and active GLP-1 concentrations were measured by ELISA 
(ALPCO, USA). The data were statistically analyzed by SPSS and significance level was accepted at 
P<0.05. 
RESULTS: Both fasting total and active GLP-1 concentrations were significantly lower in T1DM 
patients (total 0.4 pmol/L, 0-6.4, and active 0.2 pmol/L, 0-1.9) compared with healthy controls (total 
3.23 pmol/L, 0.2-5.5, and active 0.8 pmol/L, 0.2-3.6), P=0.008 for total GLP-1, P=0.001 for active 
GLP-1. After adjustment for age, sex and body mass index, binary logistic regression showed that both 
fasting total and active GLP-1 remained significantly independently lower in T1DM patients (total 
GLP-1: OR 2.43, 95%CI 1.203-4.909 and active GLP-1: OR 8.73, 95%CI 1.472-51.787).  
CONCLUSIONS: T1DM patients had independently lower the total and active GLP-1 fasting 
concentrations in comparison with healthy people that supports potential therapeutic role of incretin 
therapy, along with insulin therapy, in T1DM patients. 
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Introduction 
The new therapeutic approach in type 1 diabetes mellitus (T1DM) grounds on the fact that glucose 
homeostasis is dependent on common effects of different hormones in addition to insulin, which 
together contribute to better glucoregulation and less side effects. The role of glucagon like peptide-1 
(GLP-1) has become a focus of the scientific interest in the field of pathophysiology of T1DM, but the 
results of the published studies were unequal. Few smaller studies showed promising therapeutic effect 
of GLP-1 analogues in T1DM patients so far,1, 2-5 while some studies did not find beneficial effect of 
GLP-1 analogues in T1DM.6  
The results of published studies showed not only the lower but also the equal fasting GLP-1 
concentration in T1DM patients in comparison with non-diabetic population.7, 8 Impaired postprandial 
rise in GLP-1 was described in T1DM patients,9 explained by insulin resistance, chronic 
hyperglycemia and insulin deficiency.7 However, certain studies indicated equal postprandial GLP-1 
concentration in T1DM patients as in healthy subjects.8, 10 The results from Greenbaum et al. indicated 
equal basal and postprandial GLP-1 concentration in T1DM and in healthy people, but impaired 
incretin effect, due to β-cell destruction.11 On the other hand, Kielgast et al. described equal incretin 
effect in T1DM and in healthy controls and equal fasting GLP-1 concentrations.12  
Since GLP-1 showed positive antihyperglycemic effect in diabetes mellitus, which is still insufficient 
examined in T1DM patients, and controversies still exists regarded GLP-1 concentration in T1DM in 
relation to healthy subjects, the aim of the study was to measure fasting and postprandial GLP-1 
concentrations in T1DM patients and in healthy controls and to examine the difference in those 
concentrations between the two groups of subjects. The secondary aim of the study was to investigate 
whether there was a gender difference in the examined hormone. 
 
 
 
5 
 
Materials and Methods  
Study Population 
The cross-sectional study included 30 C-peptide negative T1DM patients and 10 healthy volunteer 
controls. The sample size was in accordance with the G-power 3.1.3. Calculation for a difference 
between 2 independent groups (t-test; total sample size 12, α=0.05, 1-β=0.88, effect size d=2.31, 
allocation ratio N2/N1 0.3). The patients were selected from the annual review at Vuk Vrhovac 
University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Zagreb, Croatia. The diagnosis 
of T1DM was defined according to the following criteria: less than 40 years at the time of the disease 
development, episode of diabetic ketoacidosis, positive autoimmune markers and continuous need for 
insulin therapy within 1 year of the diagnosis.13 Inclusion criteria for the T1DM patients were 18-65 
years of age, at least 1-year duration of T1DM, without history of cardiovascular, severe liver or 
chronic kidney disease, with glomerular filtration rate > 45 mlmin-11.73-1m2 and without adrenal 
insufficiency. The patients received intensive insulin therapy (long-acting insulin in one or two dosage 
and ultrashort-acting insulin three times daily) and took no other medication that could affect glucose 
metabolism. Ten age, gender and body mass index (BMI) matched people were included as the 
healthy control group (without diabetes mellitus, without history of cardiovascular, severe liver or 
chronic kidney disease, with glomerular filtration rate > 45 mlmin-11.73-1m2 and without adrenal 
insufficiency). The Hospital and Medical Faculty Ethical Committee approved the study protocol. 
Written informed consent was obtained from each examinee, and the study was performed in 
accordance with the Declaration of Helsinki.  
Detailed medical history, including age at diabetes diagnosis, type of insulin therapy and other 
medications were obtained. Physical examination included measuring the body weight, height and 
waist to hip ratio, and calculation of BMI. All investigations were performed in the morning, 
following an overnight fast. All patients received long-acting insulin the night before and ultrashort-
acting insulin before the breakfast. Fasting venous blood samples were drawn at 8:00 h and 
postprandial 30 minutes after the standard diabetic breakfast in T1DM and in healthy subjects. The 
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caloric amount of the meal depended on the patient’s weight and consisted of 70% carbohydrates, 25% 
proteins and 5% fat.  All healthy control subjects had also standardized breakfast. Venous blood 
samples (plasma and serum) were collected for biochemistry panel measurement, glycated hemoglobin 
(HbA1c), fasting and postprandial total GLP-1 (GLP-1 0’ and GLP-1 30’) and active GLP-1 (GLP-1 
0’ and GLP-1 30’) concentration. Plasma samples for GLP-1 were collected in BD™ P700 Blood 
Collection System for Plasma GLP-1 Preservation (BD Customer Service, USA). All samples were 
adequate stored from the collection time until analysis on -70 C. 
Laboratory Assays 
Biochemistry panel, C-peptide, HbA1c, pancreatic islet cell antibodies and serum creatinine 
concentration were assayed using routine laboratory methods. Serum creatinine (spectrophotometry, 
OLYMPUS AU400), C-peptide (chemiluminescence, ADVIA Centaur XP), HbA1c in whole blood 
(immunoturbidimetry -TINIA, COBAS INTEGRA), glutamic acid decarboxylase (GAD), tyrosine 
phosphatase-related islet antigen 2 (IA-2), (enzyme-linked immunosorbent assay (ELISA); photometer 
STATFAX 2100), islet cell antibodies (ICA) (indirect immunofluorescence on microscope). Plasma 
total GLP-1 and active GLP-1 concentrations were measured using ELISA (sandwich) commercial kit, 
Human Total GLP-1 (7-36&9-36) ELISA Kit, ALPCO, USA; Human Active GLP-1 (7-36) ELISA 
Kit, ALPCO, USA; photometer STATFAX 2100. Postprandial change in hormone concentration was 
calculated as difference between postprandial and fasting hormone concentration, expressed as delta 
(∆). 
Statistical Analysis 
Statistical analysis was done using Statistical Package for the Social Sciences (SPSS) ver. 17.0 for 
Windows. Because of small sample size variables were described as median and minimum-maximum 
range and nonparametric statistical tests were used. Nominal variables were presented as frequencies. 
The difference between two independent numerical variables was tested using Mann-Whitney test. 
Binary logistic regression analysis was used (Hosmer-Leveshow goodness-of-fit test), using OR with 
95% CI. Significant level was accepted at P<0.05.  
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Results 
Subject Demographics 
Study included 30 C-peptide negative T1DM patients and 10 healthy controls. There were 17 male and 
13 female patients, ranging in age from 20 to 59 years (median 37), with median diabetes duration of 
22 years (3-45), BMI of 24 kgm-2 (20-30), HbA1c level of 7.2 % (5.1-12.4), fasting glucose 
concentration of 6.9 mmol/L (2.5-13.1), postprandial glucose concentration of 10.2 mmol/L (2.7-
16.3), median total insulin requirement of 0.6 IUkg-1day-1 (0.32-0.94) and median creatininemia of 66 
µmol/L (43-88). According to the number of positive pancreatic islet cell antibodies, four did not have 
positive antibodies, six had 1 positive antibody, 14 had 2 positive antibodies and six patients had 3 
positive antibodies. Healthy controls included 4 males and 6 females, median age of 30 years (27-47), 
BMI of 25 kgm-2, median HbA1c level of 5.2 % (4.3-5.8) and median creatininemia of 70 µmol/L (43-
114). There was no difference in age (z=-0.907, P=0.365), gender (χ2=0.533, P=0.716) and BMI (z=-
0.395, P=0.693) between the T1DM patients and healthy controls. 
Hormone Levels  
Table 1 shows fasting and postprandial total and active GLP-1 concentrations in T1DM patients and 
healthy controls. Total and active GLP-1 concentrations at 0' were significantly lower in T1DM 
patients compared with healthy controls, P=0.008 and P=0.001, respectively. There were no 
significant differences in total and active GLP-1 concentrations at 30' neither in their postprandial 
change (∆ GLP-1) between T1DM patients and healthy controls.  
Using the multivariate binary logistic regression analysis (Table 2) total and active GLP-1 
concentrations at 0’ remained independently higher in healthy controls in the crude model, and 
remained significantly independently higher after adjustment for age, sex and BMI (total GLP-1 0’- 
OR 2.43, 95%CI 1.203-4.909 and active GLP-1 0’- OR 8.73, 95% CI 1.472-51.787).  
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There was no difference in GLP-1 concentrations between the groups of patients with T1DM 
according to the calorie intake and also to the total number of positive pancreatic islet cell antibodies. 
There was no correlation between GLP-1 with insulin requirement in T1DM patients (data not shown).  
Figure 1 shows total GLP-1 concentrations, at 0', 30' and ∆ GLP-1, in T1DM patients in relation to 
gender. Men had significantly higher total GLP-1 at 0' (P=0.02), total GLP-1 at 30' (P<0.001) and 
total ∆ GLP-1 (P=0.012) concentrations in comparison with women. There was no difference in age, 
disease duration, HbA1c, insulin requirement, BMI and creatinine level between the genders. Men had 
significantly higher waist to hip ratio in comparison with women (z=-2.952, P=0.03). Total GLP-1 30' 
concentration remained independently higher in men by binary logistic regression after adjustment for 
waist to hip ratio, disease duration, age and insulin requirement (OR 3.267, 95%CI 1.032-10.343) 
(data not shown). There was no gender difference in active GLP-1 concentrations in T1DM patients. 
In healthy controls we did not find difference in GLP-1 concentrations in relation to gender (data not 
shown). 
Discussion 
T1DM patients had independently lower fasting both total and active GLP-1, but not the postprandial 
concentrations, in comparison with healthy subjects.  The results are partial in accordance with the 
results of Vilsbøll et al. They also found lower fasting GLP-1 concentration in T1DM patients (N=8) 
in comparison with healthy controls (N=8) and no postprandial difference. We agree that 
hypothetically exogenous insulin therapy might have inhibitory effect on GLP-1.8 The hypothesis is 
additionally supported by the results of Lugari et al., who described equal fasting active GLP-1 
concentration, without postprandial rise, between T1DM and healthy controls.7 They examined 16 
T1DM patients, which received long-acting insulin the night before, but did not receive insulin before 
the breakfast. Thus, bolus insulin therapy in study of Vilsbøll and in our study might explain the lower 
fasting GLP-1 concentration in T1DM patients, by the already proposed mechanism. Greenbaum et al. 
showed equal fasting and postprandial GLP-1 concentrations between the T1DM patients (N=17) and 
healthy controls, but their patients had better glucoregulation, were younger and had lower BMI, while 
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there were no data about insulin therapy.14 Higher calorie intake was followed by higher postprandial 
GLP-1 concentration in their study, explained by food induced GLP-1 production. Our study did not 
confirm the relation, while no difference was found in postprandial GLP-1 concentration in relation to 
different calorie intake between different subjects, but we did not study different calorie intake among 
the same subjects; and our patients had smaller percentage of fats (5 %) compared with their subjects 
(33 %). Maybe the difference in fat content is responsible for that. Food stimulation of GLP-1 thus 
remains possible.  
In both groups (T1DM and healthy controls) of our study we found lower fasting and postprandial 
GLP-1 concentrations in comparison with previous results. So far, the above mentioned differences in 
GLP-1 concentrations among T1DM patients and between T1DM patients and healthy controls are 
explained by different methods of hormone measurement, different patients’ characteristics and 
difference in insulin therapy.15  
We also found the difference in total GLP-1 concentrations between the genders in T1DM patients. 
Men had significantly higher total GLP-1at 0', at 30' and higher postprandial change (∆ GLP-1) 
concentrations in comparison with women. After adjustment for age, disease duration, waist to hip 
ratio and insulin therapy, postprandial total GLP-1 concentration remained independently higher in 
men in comparison with women with T1DM. There is no study in T1DM that described GLP-1 
concentration in relation to gender. One study in non-diabetic healthy population reported higher GLP-
1 concentration in women, explaining by higher body fat percentage in women.16 We could presume 
that T1DM men had higher GLP-1 due to higher waist to hip ratio in our study; however, multivariate 
statistics disproved it. In contrast to T1DM, we did not find gender difference in GLP-1 concentration 
in healthy controls, but the sample was small for definitive conclusion. 
Study strengths and limitations 
We included T1DM patients without residual β-cell function (C-peptide negative), therefore our 
sample is more homogenous and we could eliminate endogenous insulin impact on GLP-1 
concentrations. In all subjects we measured total and active GLP-1 concentrations. Total GLP-1 
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concentration should be better indicator of overall GLP-1 secretion, while active GLP-1 possesses 
almost all biological effects in body. All subjects were adults, of same race, without significant 
difference in gender abundance, and all subjects were controlled in one center with standardized 
therapeutic approach. Thus our results could be considered region specific. It was a cross-sectional 
study, which restricted the ability to establish causality. We did not measure hormones in duplicates 
and there were single blood collection. Therefore, we were limited by reliance on the resulted data.  
Conclusion 
T1DM patients had independently lower the total and active GLP-1 fasting concentrations in 
comparison with healthy people and that supports potential therapeutic role of incretin therapy, along 
with insulin therapy, in T1DM patients. For the first time to our knowledge we found the difference in 
total GLP-1 concentrations between the genders in T1DM patients. Men with T1DM had 
independently higher total GLP-1 postprandial concentration in comparison with women, while no 
gender difference existed in healthy controls. Further, larger studies, are needed to confirm the results 
and clarify roles of GLP-1 in the pathophysiology of T1DM and possible therapeutic effect of GLP-1 
analogues. 
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Figure 1 Differences in total glucagon-like peptide 1 (GLP-1) concentrations between the gender in type 1 
diabetic mellitus patients (Mann-Whitney test; 
*
z=-2.33, P=0.02; 
†
z=-3.71, P<0.001; 
‡
z=-2,51, P=0.012) 
Table 1 Differences in GLP-1 concentration between T1DM patients and healthy controls 
(Mann-Whitney test; median, minimum-maximum) 
Variable 
 T1DM patients 
(n=30) 
 Healthy controls 
(n=10) 
z P 
GLP-1 (pmol/L) 
     Total 
       0'  
 
 
0.4 (0-6.4)
 
 
 
3.23 (0.2-5.5) 
 
 
-2.66 
 
 
0.008 
       30'  4.4 (0.5-29) 4.1 (1.6-10.9) -0.125 0.901 
       ∆ 30'-0' 3.5 (-1.9-24.3) 1.7 (0.7-6) -1.203 0.229 
     Active 
       0' 
 
0.2 (0-1.9) 
 
0.8 (0.2-3.6) 
 
-3.387 
 
0.001 
       30'  1.25 (0.09-9.7) 1.65 (0.5-6.6) -1.063 0.288 
       ∆ 30'-0' 0.91 (-0.5-9.3) 0.65 (0.1-3.4) -0.579 0.563 
*
GLP-1- glucagone like peptide-1; 
†
T1DM- type 1 diabetes mellitus, 
‡
∆30'-0'-postprandial change . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2 Binary logistic regression of fasting total and active GLP-1 in relation to healthy 
controls (N=40) 
Independent variable Model A  Model B 
total GLP-1 0’ (pmol/L) 1.493 (1.04-2.145)*
 
2.43 (1.203-4.909)
* 
active GLP-1 0’ (pmol/L) 4.332 (1.442-13.012)*
 
8.73 (1.472-51.787)
* 
*
P<0.05; OR (95% CI) from separate models; 
†
GLP-1 0'- fasting glucagone like peptide-1. 
Model A: crude. Model B: adjusted for age, sex and body mass index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
